3 hrs ago | San Francisco Business Times
Report: Bayer to boost R&D spending next year
Bayer likely will increase its research and development budget, most of which goes to its health care business, according to PharmaTimes World News.
Oculus Innovative Sciences' Development Partner, Bayer Animal Health, ...
Oculus Innovative Sciences' Development Partner, Bayer Animal Health, Receives Regulatory Approvals to Market Microcyn -Based Vetericyn Animal Healthcare Products in China and Taiwan Oculus Innovative Sciences, Inc.
Bayer HealthCare To Increase R&D Spending in 2010 as Looks to the Future
Pharmatimes.com -- At a time when many firms are cutting back on research, it looks as though Bayer will be upping its R&D spend in 2010, according to the German groupa s chairman.
Improving The Care Of People With Diabetes
Apart from the diabetes specialist, the nurse is the most important person for people with diabetes, particularly if they have questions about nutrition, blood glucose monitoring, diabetic foot or exercise.
First-Ever Leading Calcium Supplement to Help Support Bone AND Heart Health
Newswise - Bone strength and heart health are two of the most important health issues for women.
European Firms Test The Bottom
Although third-quarter sales and earnings numbers don't always support the claim, European chemical company executives contend that the worst is behind them in the economic crisis that has plagued their industry for the past 12 months.
ArcelorMittal Net Plunges 76%; Vossloh Sales Down 19%
ArcelorMittal third quarter sales fell 54% to $16.17 billion and net profit fell 76% to $903 million or $0.60 a share.
Bayer HealthCare Presents Florbetaben Phase II Study Results at World Congress of Neurology
Bayer HealthCare presented results from a global Phase II study of florbetaben, its imaging agent in development for the detection of cerebral beta-Amyloid plaques, at the 19th World Congress of Neurology .
The Bayer Group , which supplies products to the coatings and other industries, reported that its third quarter EBITDA before special items edged up by 0.4% year on year to a 1.499 billion while Q3 sales fell by 7% to a 7.392 billion compared to 2008.
Bayer Q3 net income falls 10 pct
German drugs and chemicals maker Bayer AG reported Tuesday a 10 percent drop in third-quarter net income as strong sales in health care and pharmaceuticals were offset by weaker demand for fertilizers and materials.
Bayer Group income falls in 3Q
Net income fell slightly at the Bayer Group, the parent company of Bayer Corp. , in the third quarter.
The risk of venous thromboembolism for drospirenone containing oral...
The Swiss regulatory authority Swissmedic has conducted an analysis with its expert medical committee on the latest data and studies regarding the risk of venous thromboembolism associated with oral hormonal contraceptives.
I started to look beyond Europe and decided to work in Asia. Nobody at that time was going to China for professional reasons! I saw the future staring at me and I decided to go.
Pittsburgh Selected North American Host City for World Environment Day 2010
Bayer Corporation 100 Bayer Road Pittsburgh PA 15205-9741 Phone: 412-777-5200 www.BayerUS.com Allegheny County Executive Dan Onorato joins Bayer President & CEO Greg Babe to announce selection of Pittsburgh as North America's Host City for World Environment Day 2010 PITTSBURGH - " The United Nations Environment Programme has named Pittsburgh the ...
German Unit of Bayer Goes Back to Full Work Schedule
Bayer MaterialScience AG of Leverkusen, Germany, says it will end a reduced work schedule at its German sites on November 1, putting some 4,100 workers back on full salary.
TSX Venture Exchange closes up 14.93 points to 1,322.28 on trading Tuesday
The TSX Venture Exchange settled at 1,322.28 up 14.93 points Tuesday. The volume at 5 p.m. was 242.34 million shares.
Merck-dumped Paratek Woos Novartis: $485M Antibiotic Deal
Privately held Paratek Pharmaceuticals Inc. has found another partner to help develop its antibiotic PTK 0796 for life-threatening infections, this time joining with Swiss drugmaker Novartis AG in a deal valued at up to $485 million.
Bayer accused of hiding Yaz contraceptive risk
Bayer AG, Germany's largest drugmaker, was sued by two Pennsylvania pension funds and accused of misrepresenting the safety and effectiveness of the Yaz contraceptive to boost sales.
Bayer downgraded to neutral from buy at UBS
UBS said the stock has climbed 50% from March 18 and most catalysts for 2009 have come through.
U.S. Group Sues Bayer Over Vitamin Claims
A U.S. advocacy group filed a lawsuit against German drugmaker Bayer AG, saying the company made false claims about a vitamin supplement it makes.
Also on Topix